Cyber Security etc. サイバーセキュリティ等 Vol.5

All the below tweets are in English.

取り急ぎ標記につき以下貼っておきます。


https://twitter.com/coofish1/status/1235503278198124544

Austria オーストリア

All the below links and half of the below tweets are in English, and the other half are in Japanese.

取り急ぎ標記につき以下貼っておきます。

Austria Vol.3 (universities, etc.)
Austria Vol.2 (Legislative Election & Coalition 2017)
Austria Vol.1 (Miscellaneous incl Presidential Election 2016)

ツイッター検索においてオーストリア関連等で出て来たもの


https://twitter.com/guriobi1/status/1260442750241161216

Switzerland スイス

All the below links are in English, and most of the below tweets are in Japanese.

取り急ぎ標記につき以下貼っておきます。

Switzerland Vol.4 (University of St. Gallen, etc.)
Switzerland Vol.3
Switzerland Vol.2
Switzerland Vol.1

ツイッター検索でスイス関連で出て来たもの 


https://twitter.com/VogueChange/status/1258155848788033543


@swissinfo_jp
@SCCIJ

#Coronavirus #コロナウイルス Vol.6 / Science and Technology 科学技術 Vol.6(Pharmaceutical products 医薬品 Vol.2:Drugs & Vaccines 治療薬及びワクチン)

取り急ぎ標記関連記事及びその一部抜粋を以下貼っておきます。
念のため申し上げますが、当方は(電子書籍出版時に製薬企業等につき調べましたのでほんの少しだけ予備知識があろうかとも思いますが)医薬品のいわゆる素人ですので、あくまでご参考までご覧ください。色々考える際に参考にはなるとも考えております。

Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19 (16/04/2020) | Praveen Duddu @ArenaClinical

Chloroquine approved for emergency use by US FDA
Favilavir, the first approved coronavirus drug in China

Pharmaceutical companies involved in developing coronavirus drugs/vaccines
[Novel coronavirus vaccines]
Fusogenix DNA vaccine by Entos Pharmaceuticals
… Fusogenix drug delivery platform is a proteo-lipid vehicle that introduces genetic payload directly into the cells. …
ChAdOx1 nCoV-19 by University of Oxford
…an adenovirus vaccine vector developed by the university’s Jenner Institute. …
Gimsilumab by Roivant Sciences
…a clinical-stage, human monoclonal antibody. The drug targets granulocyte-macrophage colony stimulating factor (GM-CSF), which is a pro-inflammatory cytokine found in high levels…
AdCOVID by Altimmune
…to develop a single dose intranasal vaccine for COVID-19 named AdCOVID. The company is currently carrying out immunogenicity studies after, which phase one clinical trial material will be developed. Altimmune and UAB will work with researchers to conduct preclinical animal studies and phase one clinical trial in the third quarter of 2020.
TJM2 by I-Mab Biopharma
…a neutralising antibody, as a treatment for cytokine storm in patients suffering from a severe case of coronavirus infection. The drug targets the human granulocyte-macrophage colony-stimulating factor (GM-CSF), which is responsible for acute and chronic inflammation.
Coronavirus vaccine by Medicago
…after having produced Virus-Like Particles (VLP)… …a collaboration with Laval University’s Infectious Disease Research Centre…
AT-100 by Airway Therapeutics
…novel human recombinant protein named AT-100 (rhSP-D)… AT-100 has shown efficacy in preclinical studies in reducing inflammation and infection in the lungs, while also generating an immune response against various respiratory diseases.
TZLS-501 by Tiziana Life Sciences
…monoclonal antibody named TZLS-501… …a human anti-interleukin-6 receptor (IL-6R), which helps in preventing lung damage and elevated levels of IL-6. …reducing chronic lung inflammation.
OYA1 by OyaGen
BPI-002 by BeyondSpring
…a small molecule agent indicated for treating various infections… …to activate CD4+ helper T cells and CD8+ cytotoxic T cells and generating an immune response in the body. If combined with another COVID-19 vaccine, the drug has the ability to generate long-term protection against viral infections. …
Altimmune’s intranasal coronavirus vaccine
…being developed based on a vaccine technology platform that is similar to NasoVAX, an influenza vaccine developed by Altimmune.
INO-4800 by Inovio Pharmaceuticals and Beijing Advaccine Biotechnology
NP-120 (Ifenprodil) by Algernon Pharmaceuticals
…an N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonist sold under the brand name Cerocal. …
APN01 by University of British Columbia and APEIRON Biologics
…ACE2 protein was the main receptor for the SARS virus. …
mRNA-1273 vaccine by Moderna and Vaccine Research Center
…targets the Spike (S) protein… …shipped to NIAID for phase one human clinical trial. …
Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine by MIGAL Research Institute
…efficacy in pre-clinical trials conducted by the Volcani Institute. …in the oral form. …
TNX-1800 by Tonix Pharmaceuticals
…a modified horsepox virus developed using Tonix’s proprietary horsepox vaccine platform. … Southern Research will be responsible for evaluating the efficacy of the vaccine, under the partnership.
Brilacidin by Innovation Pharmaceuticals
…a defensin mimetic drug candidate, as a potential treatment… …has shown antibacterial, anti-inflammatory and immunomodulatory properties in several clinical trials. …already investigating the drug for inflammatory bowel disease and oral mucositis in cancer patients. …has signed two material transfer agreements with a university in the US and 12 biocontainment labs in the US for evaluation…
Recombinant subunit vaccine by Clover Biopharmaceuticals
…a recombinant subunit vaccine using its patented Trimer-Tag© technology. …binding with the host cell and causing a viral infection. …successfully produced the subunit vaccine in a mammalian cell-culture based expression system… …antigen-specific antibody in the serum of fully recovered patients who were previously infected by the virus. …equipped with in-house cGMP biomanufacturing capabilities…
Vaxart’s coronavirus vaccine
…in tablet formulation using its proprietary oral vaccine platform, VAAST. …for mucosal and systemic immune responses.
CytoDyn-leronlimab
…(PRO 140), a CCR5 antagonist, as a potential coronavirus drug. …being investigated in phase two clinical trials as a treatment for HIV and has been awarded fast-track approval status…
Linear DNA Vaccine by Applied DNA Sciences and Takis Biotech
…will use Polymerase Chain Reaction (PCR)-based DNA manufacturing technology… …high purity, increased production speed, and absence of antibiotics and bacterial contaminants. …can be effective without being inserted into the patient’s genome. …based on the entire spike gene of the coronavirus, while…based on the antigenic portions of the protein.
BXT-25 by BIOXYTRAN to treat late-stage acute respiratory distress syndrome (ARDS)
…in late-stage patients infected with the coronavirus. The diffusion of oxygen to the blood is comprised in patients suffering from ARDS leading to fluid build-up in the lungs. …designed to be 5,000 times smaller than blood cells and efficiently transport oxygen through the body for a period of nine hours before being processed by the liver. The drug can help in supplying oxygen to the vital organs and enable the patient to recover and survive.
Novavax’s MERS coronavirus vaccine candidate
…designed to primarily bind to the major surface S-protein and developed using the company’s recombinant nanoparticle vaccine technology. Tested along with the Novavax’s proprietary adjuvant Matrix-M™, it inhibited infection by inducing immune responses in the laboratory studies.
Inovio Pharma’s INO-4700
…being developed by Inovio in partnership with GeneOne Life Science. It is delivered as vaccine intramuscularly, using the Cellectra® delivery device.

[Coronavirus drugs]
Remdesivir (GS-5734) by Gilead Sciences
Actemra by Roche to treat coronavirus-related complications
China approved the use of Roche’s Actemra for the treatment of severe complications… …the ability to prevent cytokine storms or overreaction of the immune system, which is considered as the main reason behind organ failure…
Biocryst Pharma’s Galidesivir, a potential antiviral for coronavirus treatment
…(BCX4430) has shown broad-spectrum activity against a wide range of pathogens… …a nucleoside RNA polymerase inhibitor that disrupts the process of viral replication. …has already shown survival benefits in patients against deadly viruses such as Ebola, Zika, Marburg, and Yellow fever. …to combat multiple potential viral threats including coronaviruses, flaviviruses filoviruses, paramyxoviruses, togaviruses, bunyaviruses, and arenaviruses.
Regeneron’s REGN3048-3051 and Kevzara
…the combination of neutralising monoclonal antibodies REGN3048 and REGN3051… Both the antibodies bind to S-protein of MERS coronavirus. …in the mouse model of MERS resulted in the high-level neutralisation of the MERS coronavirus in circulating blood with reduced viral loads in the lungs. … Kevzara is approved for the treatment of rheumatoid arthritis and is known to block the interleukin-6 (IL-6) pathway, which causes an overactive inflammatory response…
SNG001 by Synairgen Research
…an inhaled drug, is planned to be tested by the University of Southampton to treat asthma, chronic obstructive pulmonary disease and lower respiratory tract illnesses… …a formulation of naturally occurring Interferon-β, which is administered through a nebuliser and is delivered directly to the lungs to reduce the severity…
AmnioBoost by Lattice Biologics
…exploring the efficacy of its amniotic fluid concentrate, AmnioBoost, in treating acute respiratory distress syndrome (ARDS)… …for chronic adult inflammatory conditions such as osteoarthritis. …reduces the production of pro-inflammatory cytokines while boosting the production of anti-inflammatory cytokines.

Other companies developing coronavirus vaccines/drugs
Enanta Pharmaceuticals
…plans to develop antiviral drug candidates…
Predictive Oncology
…an AI Platform for the discovery and development of vaccines… …has signed an agreement with InventaBioTech to acquire Soluble Therapeutics, which provides it with access to the HSCTM Technology.
Emergent BioSolutions
…developing two plasma-derived product candidates or hyperimmunes using its hyperimmune platforms… …including vaccines for smallpox, botulism, and anthrax. … The hyperimmunes are polyclonal antibodies derived from plasma, which are capable of generating an immune response and protecting against infection. …with a severe case…
Integral Molecular
…has launched a vaccine programme using its two technology platforms including Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array. …isolate the cellular receptors that enable the virus to spread quickly. …while the Membrane Proteome Array technology is capable of identifying the receptors through which viruses infect cells.
CEL-SCI
…using its proprietary LEAPS peptide technology, which utilises conserved areas of the coronavirus proteins to generate T-cell responses and reduce viral load. …to develop immunotherapeutic peptides with both antiviral and anti-inflammatory properties. …in reducing tissue damage from inflammation caused due to lung infection, which is a major cause of mortality in elderly patients.
AJ Vaccines
…will use the latest technology to develop antigens that can mimic the native structures of the virus. …
Takeda Pharmaceutical Company
… The anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) therapy will be designed to treat high-risk patients. The H-IG therapy includes concentrated pathogen-specific antibodies derived from plasma of recovered patients. …
Heat Biologics
…using its proprietary gp96 vaccine platform. …reprogramming live cells to produce antigens that can bind to the gp96 protein and generate an immune response against those antigens.
Pfizer
…antiviral compounds…
Mateon Therapeutics
…an antiviral response programme to develop coronavirus treatments using its therapeutic and artificial intelligence (AI) platforms. …
Hong Kong University of Science and Technology
…have identified B-cell and T-cell epitopes, which are capable of generating an immune response against the SARS virus and a similar response…
Vaccine by Generex
…following a contract from a Chinese consortium comprising of China Technology Exchange, Beijing Zhonghua Investment Fund Management, Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development. The company will utilise its Ii-Key immune system activation technology to produce a COVID-19 peptide for human clinical trials.
Coronavirus drugs by Columbia University
Vaccine by Tulane University
Coronavirus vaccine by ImmunoPrecise Antibodies
…will use its B Cell Select™ and DeepDisplay™ discovery platforms to therapeutic compounds… …will be using the PolyTope mAb TherapyTM and EVQLV’s artificial intelligence platforms develop a COVID-19 therapy.
Serum Institute of India
…collaborating with Codagenix, a US-based biopharmaceutical company, to develop a cure for coronavirus using a vaccine strain similar to the original virus. …
Southwest Research Institute
…virtual screening called Rhodium…
Zydus Cadila
…two novel approaches. The first approach includes the development of a DNA vaccine against the viral membrane protein of the virus, while a live attenuated recombinant measles virus (rMV) vectored vaccine will be developed in the second approach. The rMV-based vaccine works by inducing specific neutralising antibodies…
NanoViricides
…developing a treatment for nCoV-2019 using its nanoviricide® technology. …used to develop ligands that can bind to the virus in the same way as a cognate receptor and attack various points of the virus.
Vir Biotechnology
…a clinical-stage immunology company… has identified two monoclonal antibodies that can bind to the virus… The antibodies target the spike (S) protein of the virus by entering through the cellular receptor ACE2. …a partnership with WuXi Biologics… …also partnered with Alnylam Pharmaceuticals to identify siRNA candidates… …another partnership with Biogen for cell line and process development and manufacturing…
HIV drugs for coronavirus treatment
Abbvie’s HIV protease inhibitor, lopinavir is being studied along with ritonavir for the treatment of MERS and SARS coronaviruses. …HIV infection under the trade name Kaletra®. … Lopinavir is believed to act on the intracellular processes of coronavirus replication and demonstrated reduced mortality in the non-human primates (NHP) model of the MERS. Lopinavir/ritonavir in combination with ribavirin showed reduced fatality rate and milder disease course during an open clinical trial in patients in the 2003 SARS outbreak. Cipla is also reportedly planning to repurpose its HIV drug LOPIMUNE, which is a combination of protease inhibitors Lopinavir and Ritonavir…
Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, donated its PREZCOBIX® HIV medication (darunavir/cobicistat)… Darunavir is a protease inhibitor… …as potentially having antiviral activity… …has no in vitro or clinical data… …has partnered with the Biomedical Advanced Research and Development Authority (BARDA)…

#Coronavirus #コロナウイルス Vol.5 / Science and Technology 科学技術 Vol.5(Pharmaceutical products 医薬品 Vol.1:Drugs & Vaccines 治療薬及びワクチン)

ご参考まで標記関連記事及び一部抜粋を以下貼っておきます。

Reasons for hope: The drugs, tests and tactics that may conquer coronavirus(04/17/2020) | Christine Soares @reuters,@stltoday

DRUGS
Remdesivir (Gilead Sciences)
Antiviral drug, originally developed to combat RNA viruses including respiratory syncytial virus. …antivirals work best when patients are healthier…
Hydroxychloroquine and chloroquine
Malaria drug also believed to have antiviral activity. Blocked SARS-CoV-2 entry into cells in an in-vitro experiment. …
Actemra or tocilizumab (Roche)
Monoclonal antibody approved for rheumatoid arthritis and also for treating the “cytokine storm” immune overresponse in cancer patients. …
Kevzara or sarilumab (Sanofi, Regeneron Pharmaceuticals)
Monoclonal antibody approved for inflammatory arthritis, and in trials targeting the “cytokine storm” immune response in severely ill COVID-19 patients. …
Jakavi or ruxolitinib (Novartis, Incyte)
Developed to treat inflammatory and autoimmune diseases, and in late-stage development as a cream for atopic dermatitis. …
Kaletra or lopinavir-ritonavir (Abbvie)
Antiviral combination used to treat and prevent HIV infections. …
(rhACE2) APN01 (Apeiron Biologics)
A recombinant human angiotensin converting enzyme 2 (rhACE2) under Phase-2 clinical development in ALI (Acute Lung Injury) and PAH (Pulmonal arterial hypertension). …
Camostat Mesylate (University of Aarhus, Denmark)
Protease inhibitor licensed in Japan and South Korea to treat chronic pancreatitis. In vitro experiments found it blocks a mechanism SARS-Cov-2 uses to enter human cells. … The University of Tokyo also announced plans for a trial of camostat mesylate and a related drug, nafamostat mesylate, starting as early as April 2020.
IFX-1 (InflaRx)
Monoclonal antibody targeting complement activation product C5a. Designed to block a mechanism of inflammation…
Aspirin, clopidogrel, rivaroxaban, atorvastatin, omeprazole (Imperial College, London)
Trial of cardioprotective drugs to prevent direct damage to the heart muscle that appears to drive the severity of COVID-19…

VACCINES
MRNA 1273 (Moderna/NIAID)
RNA vaccine made with messenger-RNA (mRNA) encoding the spike protein of SARS-CoV-2 encapsulated in a lipid nanoparticle. …
NVX-COV2373 (Novavax)
…enhance immune responses. …
Lentiviral minigene vaccines (LV-SMENP) (Shenzhen Geno-Immune Medical Institute)
Engineered minigenes encoding viral antigens; lentiviral vector designed to infect dendritic and T cells to induce immunity. …
BCG tuberculosis vaccine (Murdoch Children’s Research Institute; UMC Utrecht)
Bacillus Calmette-Guérin tuberculosis vaccine that induces a broad innate immune-system response, which has been shown to protect against infection or severe illness with other respiratory pathogens. …
INO-4800 (Inovio Pharmaceuticals, Coalition for Epidemic Preparedness Innovations)
DNA plasmid vaccine delivered into the skin via a patch-style electroporation device. …
AD5-NCOV (Cansino Biological Inc. / Beijing Institute of Biotechnology)
Non-replicating viral vector. …
CHADOX1 (University of Oxford)
Non-replicating chimpanzee adenovirus vector. …

#Coronavirus #コロナウイルス Vol.3 / Science and Technology 科学技術 Vol.3

What does 5G have to do with coronavirus? Where did it come from? Your questions answered (09/04/2020) | @DWNews

コロナウイルス関連説明が分かり易いので、下記抜粋をご紹介します。

Where did SARS-CoV-2 come from?
Scientific consensus agrees that the novel coronavirus is natural — it’s a zoonotic disease, meaning it was transmitted from animals to humans. It’s widely thought that the virus originated in bats, before possibly passing through another mammal that infected a human.
In early February, Nature published a study showing that the novel coronavirus is 96% identical at the whole-genome level to a bat coronavirus.
Another study found that pangolins — a scaly anteater that is heavily trafficked in parts of Asia and Africa — carry coronaviruses that are very similar to SARS-CoV-2. …

Will I die of COVID-19?
This question can’t be answered with a simple “yes” or “no,” just like death from the flu or a car accident can’t be predicted with certainty. We can only speak of probabilities. And even that is not so easy in the case of COVID-19, which is why we have prepared a detailed breakdown of the statistics here …
… the virus’ casualty rate is between 0.5 to 2%, i.e. one or two people die out of every 100 people who are infected.

How long can the virus survive in the air or on surfaces?
… But the good news is that the virus needs a live host to survive. Without a live host, the virus eventually dies out because it can’t copy itself. So while it may survive on some surfaces for hours and even days, over time it becomes less infectious because, without being able to replicate, the virus breaks down over time.
… temperature changes and sunlight — that could affect the stability of the virus.

Why isn’t there a vaccine yet?
It normally takes years to develop an effective and safe vaccine.
… there are at least 47 ongoing projects globally focussing on the development of a coronavirus vaccine. …
… Scientists at the DZIF use pre-existing “building blocks” from previously formulated vaccines to work towards the development of a coronavirus vaccine. Although the scientists are working under high pressure, it’s not possible for a vaccine to be launched on the market this year. The clinical studies, which are crucial for approval, take time.
Parallel to the development of the vaccine, some researchers are working on developing a “passive immunization” with antibodies derived from blood serum. These come from people who have survived a SARS-CoV-2 infection and therefore have antibodies in their blood that can fight the virus.
It’s called passive immunization, because the recipient body hasn’t actively produced any antibodies itself. And as a result, the antibodies it “borrows” will provide protection or help to fight an infection, but only for a short period of time. Only a traditional vaccine will provide long term protection from coronavirus. …

World 世界情勢等 Vol.4

All the below links are in English.

ご参考まで取り急ぎ以下貼っておきます。

World Vol.15 (U.S. universities) 2020年3月10日
World Vol.14 (U.S. universities) 2020年3月10日
World Vol.13 (U.S. universities) 2020年3月10日
World Vol.12 2020年3月9日
World Vol.9 2020年2月12日
World Vol.8 2020年1月27日
World Vol.7 2019年12月13日
World Vol.6 2019年11月15日
World Vol.5 2019年9月24日
World Vol.4 2019年8月23日
World Vol.3 (Indexes & Statistics) 2017年1月4日
World Vol.2 (The Global Innovation Index 2016) 2017年1月2日
World Vol.1 (The Global Competitiveness Index 2016-2017 – methodology, et al.) 2016年9月29日

“World”につき2017年から2019年8月まで少し空いていますが、世界情勢を見ていなかったということは有り得ません(笑)。
ただ、電子書籍出版等に尽力していた時期と確かに重なるので、“World”関連情報を記録として統一的に残していなかった、そこまで手が回らなかった、他のタイトルの投稿に分散している、等なのだろうと考えています。

#Coronavirus #コロナウイルス Vol.2 / World 世界情勢等 Vol.3 / Science and Technology 科学技術 Vol.2 / Crisis Management 危機管理 Vol.4

All the below links are in English.

取り急ぎ以下貼っておきます。

#Coronavirus コロナウィルス
Science and Technology Vol.21 (#coronavirus)
Science and Technology Vol.18 (#CoronaVirus)
Science and Technology Vol.19 (Artificial Intelligence to help curb #CoronaVirus) 人工知能

World
World Vol.19 (incl #coronavirus)
World Vol.18 (incl #coronavirus)
World Vol.17 (#coronavirus)
World Vol.16 (incl #coronavirus)
World Vol.11 (U.S. universities on #coronavirus)
World Vol.10 (#CoronaVirus – impact on global economy)

科学技術(コロナウイルス以外)
Science and Technology Vol.17
Science and Technology Vol.20

参考.日本の病院等のデータ(日本語)https://world-solutions-insight.blogspot.com/2020/04/hospitals.html

Ireland アイルランド Vol.14(GE2020 Vol.1)

All the below links are in English.

2020総選挙投票(2月8日)前のリンク(ツイート等)を取り急ぎ貼っておきます。
なお、この機会に書き加えさせて頂きますと、アイルランドは、イギリスという大国以外で欧州唯一の英語日常言語国であるため、各種情報を全て英語で直接理解することができる貴重な国です。
そして、イギリスの隣国であり歴史を通じた深い相互関係を現在も有するため、先月末に実現されたブレグジットの影響を最も大きく受ける国と言っても過言ではありません。
直接には同国に関係されない方々も、ブレグジットや世界の今後を考えるに当たって、今回の総選挙及びその後を見続けて損は無いと確信しております。
勿論、外国国民として、同国国民の方々を邪魔しないよう見守るのみです。
The Republic of Ireland (RoI) is the only European country other than a great power of the United Kingdom, where the English language is used on a daily basis. So she is regarded as a precious country, all the information of which we can understand directly in English.
Even now this U.K.’s neighbouring country has a profound mutual relationship with the U.K. which has been piled up throughout both of the two’s histories, so it is no exaggeration to say that she is the country which will be affected most by the Brexit.
When thinking about hereafters of the Brexit and the world, it is surely beneficial even for the people who are not involved in the RoI to keep watching the general election and its hereafter.
If we dare to say our own stance, “We have just watched and will keep watching the RoI, the U.K., the United States, etc. as foreigners who are careful not to disturb their citizens.”

Ireland Vol.61 (GE2020: miscellaneous) 8日追加
Ireland Vol.60 (GE2020: other parties) その他政党等
Ireland Vol.59 (GE2020: FG) フィナ・ゲール(統一アイルランド党;2011年3月から政権与党、2016年5月から少数単独政権)
Ireland Vol.58 (GE2020: FF) フィアナ・フォイル(共和党;2016年5月から confidence-and-supply arrangement 閣外協力)
Ireland Vol.57 (GE2020: SF) シン・フェイン
Ireland Vol.56 (GE2020)
Ireland Vol.55 (GE2020: newspapers)
Ireland Vol.53 (GE2020)

Ireland アイルランド Vol.13(電子書籍「アイルランドの政治・行政・企業・地方・大学」一部抜粋 Vol.4)

《続き》
第一章 政治機関
2.政党
(4)労働党(The Labour Party)
 ダブリン2のHume Streetにある。党首は、ブレンダン・ハウリン前公共歳出改革相(Wexford選挙区)である。
 1948-51年(コステロ政権)/54-57年(コステロ政権)/73-77年(コスグレイヴ政権)/81-82年(フィッツジェラルド政権)/82-87年(フィッツジェラルド政権)/94-97年(ブルトン政権)/2011-16年(ケニー政権)に統一アイルランド党と、92-94年(レイノルズ政権)に共和党と、連立政権を組んできた。
* 
◦ Dublin West(Joan Burton前副首相/定数4)
◦ Wexford(Brendan Howlin党首/定数5)
◦ Limerick City(Jan O’Sullivan前教育技能相/定数4)
◦ Longford-Westmeath(Willie Penrose元住宅計画担当閣外大臣/定数4)
 他方、EUにおいては、欧州人民党グループと協力関係にあり社会民主主義を謳う社会民主進歩同盟グループ(S&D)を、英国の労働党、ドイツの社会民主党、フランスの社会党などの政党と共に構成している。同グループは、2014年の選挙とその後の再編を経て191議席を占め、引き続き欧州人民党グループに次ぐ第2勢力となっている。2014年には、アイルランド労働党の得票率は国内4位で、議席は前回2009年の3から3減で0と惨敗し、無所属のNessa Childers氏1人がアイルランドからの同グループ所属となっている。

(5)緑の党(The Green Party)
 ダブリン2のSuffolk Streetにある、いわゆる環境政党である。党首は、エイモン・ライアン元通信エネルギー資源相(Dublin Bay South選挙区)である。
 2007-11年に共和党・進歩民主党(Progressive Democrats、2009年解党)と連立政権を組んだことがあり、通信エネルギー資源相及び環境遺産地方政府相のポストを占めた。
 他方、EUにおいては、欧州緑グループ・欧州自由連盟(Greens-EFA)を、他の緑の党と共に構成している。Greens-EFAは選挙後の再編も含めて2009年の57から2014年には51議席へと減らした。アイルランドの政党の中では2014年の欧州議会議員選挙の得票率は5位で、引き続き0議席のままである。

(6)その他
 2014年の欧州議会議員選挙での得票率6位以下の政党等に所属等する下院議員(カッコ内)及びその選挙区は以下のとおりである。
① Solidarity – People Before Profit
 AAA系3議席
◦ Cork North-Central(Mick Barry元コーク市議会議員/定数4)
◦ Dublin West(Ruth Coppinger元フィンガル州議会議員/定数4)
◦ Dublin South-West(Paul Murphy元Socialist Party欧州議会議員/定数5)
及び
 PBP系3議席
◦ Dún Laoghaire(Richard Boyd Barrett元Dún Laoghaire州議会議員/定数3)
◦ Dublin Mid-West(Gino Kenny元South Dublin州議会議員/定数4)
◦ Dublin South-Central(Bríd Smith元ダブリン市議会議員/定数4)
の合計6(うちダブリン圏内に5)議席を有している。
 この‘left of Labour’(労働者左派)政治グループは、Socialist Workers Party(SWP)及びSocialist Party(SP)と共に、Anti-Austerity Alliance(AAA)とPeople Before Profit(PBP) allianceにより形成され、正式に政党登録されている。
 尤も、2011年には5議席を獲得したUnited Left Alliance(ULA)でも、イデオロギーの近いSPとSWPは主な勢力であった。他方、両者は歴史的なライバルであり緊張関係があった上、前者はsectarianism、後者はconservatismという体質の違いもある。

② Independents 4 Change
◦ Wexford (Mick Wallace党首〔元建設会社職員〕/定数5)
◦ Dublin South-Central(Joan Collins元ULA下院議員/定数4)
◦ Dublin Fingal (Clare Daly元ULA・元Fingal州議会議員/定数5)
に合計3(うちダブリン圏内に2)議席を有している。

③ Social Democrats
◦ Dublin North-West(Róisín Shortall党首・元労働党下院議員・元保健省副大臣/定数3)
◦ Kildare North(Catherine Murphy元Kildare州議会議員/定数4)
に合計2議席を有しているとされている。

④ Workers & Unemployed Action
◦ Tipperary(Seamus Healy下院議員/定数5)
に1議席を有している。

⑤ 無所属Independent
◦ Donegal(Thomas Pringle元シンフェイン党ドニゴール州議会議員/定数5)
◦ Longford-Westmeath(Kevin Boxer Moran元共和党ウェストミーズ州議会議員/定数4)
◦ Dublin Bay North(Tommy Broughan元労働党下院議員;Finian McGrath障碍対策閣外大臣・元ダブリン市議会議員/定数5)
◦ Dublin Central(Maureen O’Sullivan下院議員/定数3)
◦ Dublin South-West(Katherine Zappone子供若者相/定数5)
◦ Dublin Rathdown(Shane Peter Nathaniel Ross元上院議員/定数3)
◦ Galway East(Seán Canney元ゴールウェイ州議会議員/定数3)
◦ Galway West(Noel Grealish元ゴールウェイ州議会議員;Catherine Connolly元ゴールウェイ市議会議員/定数5)
◦ Roscommon-Galway(Denis Naughten通信気候変動環境相・元統一アイルランド党上院議員;Michael Fitzmaurice元ゴールウェイ州議会議員/定数3)
◦ Clare(Michael Harty下院議員/定数4)
◦ Tipperary(Michael Lowry元交通エネルギー通信相;Mattie McGrath元サウスティペラリー州議会議員/定数5)
◦ Waterford(John Halligan教育技能省訓練技能イノベーション研究開発担当閣外大臣/定数4)
◦ Cork South-West(Michael Collins下院議員/定数3)
◦ Kerry(Danny Healy-Rae下院議員;Michael Healy-Rae下院議員/定数5。両者は兄弟である。)
に合計19議席ある。

⑤ 国会に議席を持たないが地方議会に議席を持つ政党としては、Workers’ Party of Ireland (1905年に創立されたシンフェイン党をルーツとする政党)、などがある。

当ウェブサイトにおける今般の一部抜粋はひとまずここまでとする予定です。